<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040194</url>
  </required_header>
  <id_info>
    <org_study_id>AM-101-CL-12-02</org_study_id>
    <nct_id>NCT02040194</nct_id>
  </id_info>
  <brief_title>AM-101 in the Treatment of Acute Tinnitus 3</brief_title>
  <acronym>TACTT3</acronym>
  <official_title>Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auris Medical AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auris Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety and effectiveness of the study drug,&#xD;
      AM-101. AM-101 is tested for the treatment of tinnitus that started as the result of an&#xD;
      injury to the inner ear or due to middle ear inflammation (otitis media). Subjects with&#xD;
      tinnitus can take part in the study, if their tinnitus started within the last 3 months or&#xD;
      within the last &gt;3 to 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of&#xD;
      repeated intratympanic AM-101 injections in the treatment of acute peripheral tinnitus (up to&#xD;
      3 months (Stratum A), or between &gt;3 and 6 months (Stratum B) from onset).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 28, 2017</completion_date>
  <primary_completion_date type="Actual">December 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy endpoint - alternate primary efficacy endpoints: Tinnitus Functional Index (TFI)</measure>
    <time_frame>Baseline to Day 84</time_frame>
    <description>Improvement in TFI total score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy endpoint - alternate primary efficacy endpoints: Patient-reported Tinnitus loudness on a Numerical Rating Scale (TLQ NRS loudest)</measure>
    <time_frame>Baseline to Day 84</time_frame>
    <description>Improvement in TLQ NRS loudest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoint: Hearing threshold</measure>
    <time_frame>Baseline to Day 35</time_frame>
    <description>Occurrence of deterioration in hearing threshold &gt;= 15 decibel (dB) at the average of two contiguous test frequencies (air conduction) in the treated ear(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint - TFI</measure>
    <time_frame>Baseline to Day 10 and Day 35</time_frame>
    <description>Improvement in TFI total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint - TLQ NRS loudest</measure>
    <time_frame>Baseline to Day 10 and Day 35</time_frame>
    <description>Improvement in patient-reported tinnitus loudness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint - patient-reported tinnitus annoyance (TAQ NRS worst)</measure>
    <time_frame>Baseline to Day10, Day 35 and Day 84</time_frame>
    <description>Improvement in TAQ NRS worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint - TFI sleep score</measure>
    <time_frame>Baseline to Day10, Day 35 and Day 84</time_frame>
    <description>Improvement in TFI sleep score. The subscale &quot;sleep&quot; will be evaluated only for subjects with a TFI Sleep score greater than 0 at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy endpoint - Patient global impression of change in tinnitus severity (PGIC Tinnitus)</measure>
    <time_frame>at Day10, Day 35 and Day 84</time_frame>
    <description>Patient global impression of change in tinnitus severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint - Hearing threshold</measure>
    <time_frame>Baseline to Day 1, Day 2, Day 10 and Day 84</time_frame>
    <description>Occurrence of deterioration in hearing threshold &gt;= 15 dB at the average of two contiguous test frequencies in the treated ear(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint - Hearing threshold</measure>
    <time_frame>Baseline to Day 1, Day 2, Day 10 and Day 84</time_frame>
    <description>Difference in occurrence of deterioration in hearing threshold &gt;= 15 dB at the average of two contiguous test frequencies between the treated and untreated contralateral ear (subjects with unilaterally treated tinnitus only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint - AEs and SAEs</measure>
    <time_frame>Up to Day 84</time_frame>
    <description>Occurence and severity of adverse events (AEs) and serious adverse Events (SAEs), differentiated by relatedness, and by treatment-emergence and procedure-emergence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">893</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>AM-101 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM-101</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM-101</intervention_name>
    <description>AM-101 gel for intratympanic injection</description>
    <arm_group_label>AM-101 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gel for intratympanic injection</description>
    <arm_group_label>Placebo injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Persistent subjective peripheral tinnitus (unilateral or bilateral) following&#xD;
             traumatic cochlear injury (acute acoustic trauma, blast trauma, middle ear surgery,&#xD;
             inner ear barotrauma, tympanic membrane trauma) or otitis media with onset no longer&#xD;
             than 3 months (Stratum A) or between &gt;3 months and 6 months (Stratum B) prior to&#xD;
             randomization, as documented by medical report or by documented medical history. Upon&#xD;
             implementation of protocol amendment 6, subjects with tinnitus following traumatic&#xD;
             cochlear injury will only be eligible if they are affected only unilaterally.&#xD;
&#xD;
          2. Age ≥ 18 years and ≤ 75 years;&#xD;
&#xD;
          3. Negative pregnancy test (woman of childbearing potential);&#xD;
&#xD;
          4. Willing and able to use adequate hearing protection, respectively to refrain from&#xD;
             engaging in activities or work involving loud noise exposure where sufficient hearing&#xD;
             protection is not possible or ensured;&#xD;
&#xD;
          5. Willing and able to protect ear canal and middle ear from water exposure as long as&#xD;
             tympanic membrane is not fully closed.&#xD;
&#xD;
        Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fluctuating tinnitus;&#xD;
&#xD;
          2. Intermittent tinnitus;&#xD;
&#xD;
          3. Tinnitus resulting from traumatic head or neck injury;&#xD;
&#xD;
          4. Presence of chronic tinnitus;&#xD;
&#xD;
          5. Meniere's Disease, history of endolymphatic hydrops, or history of fluctuating hearing&#xD;
             loss;&#xD;
&#xD;
          6. History of repeated idiopathic sudden sensorineural hearing loss or history of&#xD;
             acoustic neuroma;&#xD;
&#xD;
          7. Ongoing acute or chronic otitis media or otitis externa;&#xD;
&#xD;
          8. Other treatment of tinnitus for the study duration;&#xD;
&#xD;
          9. Known hypersensitivity, allergy or intolerance to the study medication or any history&#xD;
             of severe, abnormal drug reaction;&#xD;
&#xD;
         10. Women who are breast-feeding, pregnant or who are planning to become pregnant during&#xD;
             the study;&#xD;
&#xD;
         11. Women of childbearing potential who are unwilling or unable to practice contraception,&#xD;
             such as hormonal contraceptives, double barrier, sexual abstinence or intercourse with&#xD;
             a partner who has been vasectomised for at least three months;&#xD;
&#xD;
         12. Concurrent participation in another clinical study or participation in another&#xD;
             clinical study within 30 days prior to randomization.&#xD;
&#xD;
        Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Please check the study webpage below for a study site list</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

